Plasma‐soluble urokinase plasminogen activator receptor (suPAR) levels in Behçet's disease and correlation with disease activity. (12th May 2016)

• Record Type: Journal Article
• Authors: Saylam Kurtipek, Gulcan; Kesli, Recep; Tuncez Akyurek, Fatma; Akyurek, Fikret; Ataseven, Arzu; Terzi, Yuksel
• Is Part Of: International journal of rheumatic diseases. Volume 21:Number 4(2018)
• Page Start: 866
• Page End: 870
• Publication Date: 2016-05-12
• Subjects: Behçet's disease -- C‐reactive protein -- inflammation -- suPAR; Rheumatology -- Periodicals; Rheumatology -- Asia -- Periodicals; Rheumatology -- Pacific Area -- Periodicals; Rheumatic Diseases -- Periodicals; Connective Tissue Diseases -- Periodicals; Immune System Diseases -- Periodicals; 616.723
• DOI: 10.1111/1756-185X.12873
• Languages: English
• ISSNs: 1756-1841

Abstract

Abstract: Background: Soluble urokinase plasminogen activator receptor (suPAR), a new biomarker, is a soluble form of membrane‐bound receptors secreted from different immune cells. The aim of the present study is to determine plasma suPAR levels in Behçet's disease and their correlation with disease activity. Methods: Thirty Behçet's disease patients determined according to the International Study Group criteria for Behçet's disease diagnosis and 41 healthy subjects were included in the present study. Micro‐enzyme‐linked immunosorbent assay was employed to obtain quantitative data. Data of both groups were statistically analyzed. Results: The comparison of C‐reactive protein and suPAR plasma levels of the control and Behçet's disease group revealed statistically significant differences (respectively, P = 0.003 < 0.05 and P = 0.020 < 0.05). However, plasma suPAR levels related with disease activity revealed no statistically significant differences ( P > 0.05). Conclusion: The present study is the first study analyzing suPAR levels in Behçet's disease patients and their correlation with disease activity. However, further prospective studies with larger patient series using suPAR as a new plasma biomarker are required to diagnose and monitor Behcet's disease and to support the findings of the present study.